Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO) (JN060016)

Name: Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO)
Brand: abinScience
SKU: JN060016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	JN060016
Description	Tefibazumab (JN060016) is a research-grade recombinant antibody targeting clfAClumping factor A. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Staphylococcus aureus
Applications	ELISA, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa
Système d'expression	Mammalian cells
Cible	clfA Clumping factor A
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q53653, Q2G015, Q5HHM8
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	Aurexis, 521079-87-8
Contexte	Clumping factor A (clfAClumping factor A) is a ~97 kDa protein. Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis.
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

SEC-HPLC detection for Research Grade Tefibazumab.
SDS-PAGE

SDS-PAGE for Research Grade Tefibazumab.

Reférences

Fiche technique

Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Protéines Recombinantes

Anticorps

Kits d'Essai